Safety data were pooled and analyzed from one phase 2 and two phase 3 double-blind, placebo-controlled, repeat-dose systemic lupus erythematosus (SLE) trials of belimumab 1, 4 (phase 2 only), and 10 mg/kg. Types and rates of adverse events (AEs) were similar across treatment groups. Rates of patients experiencing any serious AE were 16.6%, 19.5%, 13.5%, and 18.0% with placebo, and belimumab 1, 4, and 10 mg/kg, respectively; rates of serious infusion reactions (including hypersensitivity reactions) occurring on the same days as infusions were 0.4%, 0.9%, 0%, and 0.9%, and rates of serious infections were 5.5%, 7.1%, 6.3%, and 5.3%. Malignancy rates/100 patient-years (excluding non-melanoma skin cancer) were 0.29 with placebo vs. 0.20 with all belimumab doses combined; mortality rates/100 patient-years were 0.43 vs. 0.73. These data support the conclusion that belimumab in combination with standard SLE therapy was generally well tolerated in a predominantly autoantibody-positive population with active SLE. ClinicalTrials.gov identifiers: LBSL02: NCT00071487; BLISS-52: NCT00424476; BLISS-76: NCT00410384.
CancroMPD’CruzADPKhamashtaMA. The role of B lymphocyte stimulator (BLyS) in systemic lupus erythematosus. J Clin Invest2009; 119: 1066–1073.
2.
RahmanAIsenbergDA. Systemic lupus erythematosus. N Engl J Med2008; 358: 929–939.
3.
BernatskySBoivinJ-FJosephL. Mortality in systemic lupus erythematosus. Arthritis Rheum2006; 54: 2250–2257.
4.
CampbellRJrCooperGSGilkesonGS. Two aspects of the clinical and humanistic burden of systemic lupus erythematosus: mortality risk and quality of life early in the course of disease. Arthritis Rheum2008; 59: 458–464.
5.
Parikh-PatelAWhiteRHAllenM. Cancer risk in a cohort of patients with systemic lupus erythematosus (SLE) in California. Cancer Causes Control2008; 19: 887–994.
6.
UrowitzMBGladmanDIbañezD. Accumulation of coronary artery disease risk factors over three years: data from an international inception cohort. Arthritis Rheum2008; 59: 176–180.
7.
ThumbooJStrandV. Health-related quality of life in patients with systemic lupus erythematosus: an update. Ann Acad Med Singapore2007; 36: 115–122.
8.
LesleyRXuYKalledSL. Reduced competitiveness of autoantigen-engaged B cells due to increased dependence on BAFF. Immunity2004; 20: 441–453.
9.
ThienMPhanTGGardamS. Excess BAFF rescues self-reactive B cells from peripheral deletion and allows them to enter forbidden follicular and marginal zone niches. Immunity2004; 20: 785–798.
10.
PetriMStohlWChathamW. Association of plasma B lymphocyte stimulator levels and disease activity in systemic lupus erythematosus. Arthritis Rheum2008; 58: 2453–2459.
11.
FurieRPetriMZamaniO. BLISS-76 Study Group. A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus. Arthritis Rheum2011; 63: 3918–3930.
12.
NavarraSVGuzmánRMGallacherAE. Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial. Lancet2011; 377: 721–731.
13.
WallaceDJStohlWFurieRA. A phase II, randomized, double-blind, placebo-controlled, dose-ranging study of belimumab in patients with active systemic lupus erythematosus. Arthritis Rheum2009; 61: 1168–1178.
14.
HochbergMC. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum1997; 40: 1725–1725.
15.
NavarraSVLeynesMS. Infections in systemic lupus erythematosus. Lupus2010; 19: 1419–1424.
16.
BernatskySBoivinJ-FJosephL. An international cohort study of cancer in systemic lupus erythematosus. Arthritis Rheum2005; 52: 1481–1490.
17.
KissEKovacsLSzodorayP. Malignancies in systemic lupus erythematosus. Autoimmun Rev2010; 9: 195–199.
18.
BachenEAChesneyMACriswellLA. Prevalence of mood and anxiety disorders in women with systemic lupus erythematosus. Arthritis Care Res2009; 61: 822–829.
19.
HanlyJGUrowitzMBSanchez-GuerreroJ. Neuropsychiatric events at the time of diagnosis of systemic lupus erythematosus. Arthritis Rheum2007; 56: 265–273.
20.
HarrisECBarracloughBM. Suicide as an outcome for medical disorders. Medicine1994; 73: 281–296.
Systemic lupus erythematosus (SLE or lupus). Centers for Disease Control and Prevention Web site. 2011. Available at: http://www.cdc.gov/arthritis/basics/lupus.htm10 (Updated 1 August 2011, accessed 15 March 2012).
23.
Lockshin MD, Kim M, Laskin CA, et al. Prediction of adverse pregnancy outcome by the presence of lupus anticoagulant, but not anticardiolipin antibody, in patients with antiphospholipid antibodies. Arthritis Rheum 2012; 64: 2311–2318.
24.
Cortes-HernandezJOrdi-RosJParedesF. Clinical predictors of fetal and maternal outcome in systemic lupus erythematosus: a prospective study of 103 pregnancies. Rheumatology2002; 41: 643–650.
25.
MoladYBorkowskiTMonseliseA. Maternal and fetal outcome of lupus pregnancy: a prospective study of 29 pregnancies. Lupus2005; 14: 145–151.
26.
AndradeRSanchezMLAlarcónGS. Adverse pregnancy outcomes in women with systemic lupus erythematosus from a multiethnic US cohort: LUMINA (LUI). Clin Exp Rheumatol2008; 26: 268–274.
27.
ClowseMEBMagderLSWitterF. The impact of increased lupus activity on obstetric outcomes. Arthritis Rheum2005; 52: 514–521.
28.
RahmanPGladmanDDUrowitzMD. Clinical predictors of fetal outcome in systemic lupus erythematosus. J Rheumatol1998; 25: 1526–1530.
29.
Manzi S, Sánchez-Guerrero J, Merrill JT, et al; on behalf of the BLISS-52 and BLISS-76 Study Groups. Effects of belimumab, a B lymphocyte stimulator-specific inhibitor, on disease activity across multiple organ domains in patients with systemic lupus erythematosus: combined results from two phase III trials. Ann Rheum Dis 2012; 71: 1833–1838.
